http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111848580-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate | 2020-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111848580-B |
| titleOfInvention | Crystal form of quinoline compound containing 1,2, 4-triazine-3, 5-diketone as well as preparation method and application thereof |
| abstract | The invention belongs to the technical field of chemical drugs and crystal form processes, and particularly relates to a crystal form of a quinoline compound, and a preparation method and application thereof. The crystal form of the quinoline compound is characterized by means of X-ray powder diffraction, differential thermal analysis, thermogravimetric analysis, infrared spectrum and the like. It can form a crystalline state with characteristic diffraction peaks at 3.3 DEG and 18.1 DEG with a tolerance of + -0.2 deg. And the purity is high, the stability is good, and the wetting is not easy to cause, so that the preparation method can be used for preparing medicines for preventing and/or treating cancers caused by the abnormal high expression of EGFR or VEGFR-1 tyrosine kinase. |
| priorityDate | 2019-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 59.